Respiratory Viruses Vaccine Study

RSV, hMPV and PIV3 are three highly contagious viruses that cause respiratory infections in people of all ages, but they are particularly dangerous for older adults, infants, and those with weakened immune systems. These viruses affect the lungs and airways, leading to symptoms like coughing, wheezing, shortness of breath, fatigue, and fever. While many recover fully, older adults are at greater risk for complications such as pneumonia and hospitalisation. These infections are highly prevalent and often go undiagnosed, impacting quality of life by limiting mobility, sleep, and independence. For many, even a mild illness can have lasting effects on health and wellbeing. 

Currently, there are no widely available vaccines for hMPV or PIV3.  While there are RSV vaccines available in Australia, it would be highly beneficial to have a vaccine that can target not only RSV but also hMPV and PIV3.  

This study is evaluating an investigational combination vaccine against illness caused by RSV, hMPV and PIV3 in one injection. The study aims to evaluate if the vaccine will produce antibodies against the 3 viruses. The impact of this research may be life changing – not only improving individual health but also protecting vulnerable populations worldwide.  

Participants will be randomly assigned to either the investigational vaccine, a comparator vaccine, or a placebo (inactive substance) given as an intramuscular injection . 

Each participant will receive one injection at the beginning of the study. 

The injection is administered by our trained clinical staff during a scheduled visit to our clinic, and participants will be closely monitored afterward to ensure their safety.  

Why join this clinical research study?  

- Help develop a new vaccine to protect against serious respiratory infections  

- Gain early access to new potential treatments at no cost 

- Receive health checks and advice from our professional medical team